MGS Pharma SRL
MGS Pharma reported total assets of 68,803 € at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Apr 2026).
The score of MGS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
MGS Pharma's annual accounts
| 2025 | |
|---|---|
| Net result | 54,885 € |
| Equity | 54,552 € |
| Cash | 63,690 € |
| EBITDA | 69,967 € |
| Total assets | 68,803 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Apr 2026
MGS Pharma's financial analysis
- Solvency79.3%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of MGS Pharma
MGS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1014.761.540
- VAT number
- BE1014761540
- Peppol
- Registered · 0208:1014761540 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 07 Oct 2024
- Registered office
- 4970 Stavelot
- Latest accounts
- 2025 · filed on 24 Apr 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
MGS Pharma (SRL) has been based in Stavelot since 2024, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 54,885 € and equity of 54,552 €; its revenue is not published. Its solvency stands at 79.3%, above the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to MGS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Yascare Retail sale of pharmaceutical products Uccle · balance sheet 34,424 €
- Tilosa Retail sale of pharmaceutical products Lokeren · balance sheet 70,195 €
- Itipharma Ghyselen Retail sale of pharmaceutical products Soignies · balance sheet 61,934 €
- NT Farma Retail sale of pharmaceutical products Mouscron · balance sheet 56,255 €
- Helephar Retail sale of pharmaceutical products Wingene · balance sheet 55,332 €
- Van Aelst Leonie Retail sale of pharmaceutical products Beernem · balance sheet 86,688 €
- Kato van Vooren Retail sale of pharmaceutical products Dendermonde · balance sheet 88,886 €
- Vanfleteren Pieter Retail sale of pharmaceutical products Antwerp · balance sheet 52,894 €
Frequently asked questions about MGS Pharma
What is the revenue of MGS Pharma?
MGS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of MGS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE1014761540 for MGS Pharma, if the company is VAT-registered. Its company number (CBE) is 1014.761.540.
Where is the registered office of MGS Pharma?
According to the CBE register, the registered office of MGS Pharma is in 4970 Stavelot.
What is the equity of MGS Pharma?
At the close of the 2025 financial year, the equity of MGS Pharma amounts to 54,552 €, a solvency of 79.3% of total assets.
Who manages MGS Pharma?
The register lists 1 active mandates at MGS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of MGS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →